- Home
- DVA vs NBIX Comparison
DVA vs NBIX Comparison
Compare DVA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- NBIX
- Stock Information
- Founded
- DVA 1994
- NBIX 1992
- Country
- DVA United States
- NBIX United States
- Employees
- DVA N/A
- NBIX N/A
- Industry
- DVA Misc Health and Biotechnology Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DVA Health Care
- NBIX Health Care
- Exchange
- DVA Nasdaq
- NBIX Nasdaq
- Market Cap
- DVA 12.6B
- NBIX 13.7B
- IPO Year
- DVA 1995
- NBIX 1996
- Fundamental
- Price
- DVA $173.05
- NBIX $150.71
- Analyst Decision
- DVA Hold
- NBIX Buy
- Analyst Count
- DVA 5
- NBIX 21
- Target Price
- DVA $153.40
- NBIX $165.40
- AVG Volume (30 Days)
- DVA 533.7K
- NBIX 905.8K
- Earning Date
- DVA 02-11-2025
- NBIX 02-10-2025
- Dividend Yield
- DVA N/A
- NBIX N/A
- EPS Growth
- DVA 41.03
- NBIX 97.40
- EPS
- DVA 9.24
- NBIX 3.73
- Revenue
- DVA $12,666,614,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- DVA $6.18
- NBIX $27.18
- Revenue Next Year
- DVA $3.58
- NBIX $17.92
- P/E Ratio
- DVA $18.74
- NBIX $40.43
- Revenue Growth
- DVA 6.34
- NBIX 25.72
- 52 Week Low
- DVA $107.44
- NBIX $110.95
- 52 Week High
- DVA $178.75
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- DVA 70.13
- NBIX 75.13
- Support Level
- DVA $167.57
- NBIX $145.97
- Resistance Level
- DVA $170.80
- NBIX $144.24
- Average True Range (ATR)
- DVA 3.66
- NBIX 3.56
- MACD
- DVA 1.75
- NBIX 0.50
- Stochastic Oscillator
- DVA 79.39
- NBIX 87.90
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.